New drug combo shows promise in shrinking stomach tumors before surgery

NCT ID NCT06576921

First seen Dec 29, 2025 · Last updated May 15, 2026 · Updated 15 times

Summary

This study tests whether adding the drug serplulimab to standard chemotherapy before surgery can better shrink advanced stomach or gastroesophageal junction cancer. About 116 adults will receive either the combination or chemo alone for three cycles before and after surgery. The main goal is to see if more tumors completely disappear after treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STOMACH NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Department of Digestive surgery, Xijing Hospital of Digestive Diseases, Air Force Medical University, Xi' an, China

    RECRUITING

    Xi'an, Shaanxi, 710032, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Department of General Surgery, Tangdu Hospital, Air Force Medical University

    RECRUITING

    Xi'an, Shaanxi, 710032, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Department of General Surgery, The 986th Military Hospital, Air Force Medical University

    RECRUITING

    Xi'an, Shaanxi, 710032, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The fourth hospital of Hebei Medical University

    RECRUITING

    Shijiazhuang, Heibei Province, 050000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Tianjin Medical University Cancer Institute & Hospital

    RECRUITING

    Tianjin, 300060, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.